Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib

Yamashima,Mio; Miyaaki,Hisamitsu; Honda,Takuya; Shibata,Hidetaka; Miuma,Satoshi; Taura,Naota; Nakao,Kazuhiko

doi:10.3892/mco.2017.1321

Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib

Authors:
- Mio Yamashima
- Hisamitsu Miyaaki
- Takuya Honda
- Hidetaka Shibata
- Satoshi Miuma
- Naota Taura
- Kazuhiko Nakao
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852‑8501, Japan
Published online on: July 13, 2017 https://doi.org/10.3892/mco.2017.1321
Pages: 449-453

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sarcopenia has been reported to be associated with the prognosis of patients with liver cirrhosis and hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sarcopenia was associated with the prognosis of patients with HCC treated with sorafenib. A total of 40 patients with HCC who were treated with sorafenib were evaluated. As an indicator of skeletal muscle mass, transverse psoas muscle thickness (TPMT) was measured on computed tomography images at the level of the umbilicus prior to treatment initiation and after 1‑3 months of treatment. Pre‑TPMT/height was not associated with progression‑free survival (PFS) or overall survival (OS). The change in TPMT/height prior to and following treatment was also not associated with PFS; however, the change of TPMT/height was an independent factor affecting OS (P=0.020). A total of 40 patients were divided into two groups depending on the degree of TPMT/height loss (mild and severe muscle atrophy groups). Patients with mild muscle atrophy exhibited a significantly longer OS compared with patients with severe muscle atrophy (P=0.045). Thus, the change in skeletal muscle thickness calculated as TPMT/height may be a simple predictor of survival for patients with HCC treated with sorafenib.

View Figures

View References

1	Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V, Montano-Loza AJ and Myers RP: Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value. Liver Transpl. 18:1209–1216. 2012. View Article : Google Scholar : PubMed/NCBI
2	Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG and Sawyer MB: Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 10:166–173.e1. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, Takai K, Shimizu M and Moriwaki H: Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 31:193–199. 2015. View Article : Google Scholar : PubMed/NCBI
4	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K and Nishiguchi S: Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 46:951–963. 2016. View Article : Google Scholar : PubMed/NCBI
5	Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, Kochi T, Suetsugu A, Shiraki M and Shimizu M: Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. Int J Mol Sci. 16:9612–9624. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hiraoka A, Hirooka M, Koizumi Y, Izumoto H, Ueki H, Kaneto M, Kitahata S, Aibiki T, Tomida H, Miyamoto Y, et al: Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 47:558–565. 2017. View Article : Google Scholar : PubMed/NCBI
7	Durand F, Buyse S, Francoz C, Laouénan C, Bruno O, Belghiti J, Moreau R, Vilgrain V and Valla D: Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 60:1151–1157. 2014. View Article : Google Scholar : PubMed/NCBI
8	Liver Cancer Study Group of Japan, corp-author. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th. Kanehara & Co., Ltd.; Tokyo: pp. 242009
9	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
11	Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 57:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, et al: Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. Aliment Pharmacol Ther. 34:1193–1201. 2011. View Article : Google Scholar : PubMed/NCBI
13	Montano-Loza AJ: Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol. 20:8061–8071. 2014. View Article : Google Scholar : PubMed/NCBI
14	Periyalwar P and Dasarathy S: Malnutrition in cirrhosis: Contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 16:95–131. 2012. View Article : Google Scholar : PubMed/NCBI
15	Toshikuni N, Arisawa T and Tsutsumi M: Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol. 20:7286–7297. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kaibori M, Ishizaki M, Matsui K, Nakatake R, Yoshiuchi S, Kimura Y and Kwon AH: Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. Am J Surg. 206:202–209. 2013. View Article : Google Scholar : PubMed/NCBI
17	Sanada K, Miyachi M, Tanimoto M, Yamamoto K, Murakami H, Okumura S, Gando Y, Suzuki K, Tabata I and Higuchi M: A cross-sectional study of sarcopenia in Japanese men and women: Reference values and association with cardiovascular risk factors. Eur J Appl Physiol. 110:57–65. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tanimoto Y, Watanabe M, Sun W, Hirota C, Sugiura Y, Kono R, Saito M and Kono K: Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. Arch Gerontol Geriatr. 54:e230–e233. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hiraoka A, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, et al: Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: Computed tomography is useful for evaluation. J Gastroenterol. 50:1206–1213. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yoshizumi T, Shirabe K, Nakagawara H, Ikegami T, Harimoto N, Toshima T, Yamashita Y, Ikeda T, Soejima Y and Maehara Y: Skeletal muscle area correlates with body surface area in healthy adults. Hepatol Res. 44:313–318. 2014. View Article : Google Scholar : PubMed/NCBI